Madrigal Common Stock Total Equity vs Short Term Debt Analysis
MDGL Stock | USD 220.06 2.89 1.33% |
Madrigal Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Madrigal Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Madrigal Pharmaceuticals is a good investment. Please check the relationship between Madrigal Pharmaceuticals Common Stock Total Equity and its Short Term Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.
Common Stock Total Equity vs Short Term Debt
Common Stock Total Equity vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Madrigal Pharmaceuticals Common Stock Total Equity account and Short Term Debt. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Madrigal Pharmaceuticals' Common Stock Total Equity and Short Term Debt is 0.81. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Madrigal Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Madrigal Pharmaceuticals' Common Stock Total Equity and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Madrigal Pharmaceuticals are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Common Stock Total Equity i.e., Madrigal Pharmaceuticals' Common Stock Total Equity and Short Term Debt go up and down completely randomly.
Correlation Coefficient | 0.81 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Short Term Debt
Most indicators from Madrigal Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Madrigal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.At this time, Madrigal Pharmaceuticals' Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 75.06 this year, although Enterprise Value Over EBITDA will most likely fall to (12.00).
Madrigal Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Madrigal Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Madrigal Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 442.1M | 287.0M | 273.3M | 362.6M | 640.5M | 672.6M | |
Total Stockholder Equity | 416.6M | 240.0M | 196.1M | 197.4M | 405.3M | 425.6M | |
Common Stock Shares Outstanding | 15.4M | 15.4M | 16.5M | 17.1M | 18.7M | 19.6M | |
Liabilities And Stockholders Equity | 442.1M | 287.0M | 273.3M | 362.6M | 640.5M | 672.6M | |
Other Stockholder Equity | 639.6M | 665.4M | 863.5M | 1.2B | 1.7B | 1.8B | |
Total Liab | 25.5M | 47.0M | 77.2M | 165.2M | 235.2M | 247.0M | |
Other Current Liab | 23.6M | 45.2M | 55.0M | 91.5M | 90.0M | 94.5M | |
Total Current Liabilities | 25.1M | 46.6M | 76.8M | 115.9M | 118.5M | 124.5M | |
Property Plant And Equipment Net | 1.9M | 1.8M | 1.6M | 1.2M | 3.3M | 2.1M | |
Net Debt | (46.0M) | (53.2M) | (35.5M) | (281.7M) | 17.3M | 18.1M | |
Retained Earnings | (223.2M) | (425.5M) | (667.3M) | (962.7M) | (1.3B) | (1.3B) | |
Accounts Payable | 1.2M | 1.0M | 21.4M | 23.8M | 28.0M | 29.4M | |
Cash | 46.7M | 54.0M | 36.3M | 331.5M | 99.9M | 99.8M | |
Non Current Assets Total | 1.9M | 1.8M | 1.6M | 1.2M | 3.3M | 2.4M | |
Non Currrent Assets Other | 1.9M | 1.8M | 797K | 1.2M | 1.4M | 719.9K | |
Cash And Short Term Investments | 439.0M | 284.1M | 270.3M | 358.8M | 634.1M | 665.8M | |
Short Term Investments | 392.3M | 230.1M | 234.1M | 27.2M | 534.2M | 560.9M | |
Other Current Assets | 1.2M | 1.0M | 1.3M | 2.6M | 3.2M | 3.3M | |
Property Plant And Equipment Gross | 1.9M | 1.8M | 1.6M | 1.2M | 3.3M | 2.1M | |
Total Current Assets | 440.2M | 285.2M | 271.7M | 361.4M | 637.3M | 669.1M | |
Accumulated Other Comprehensive Income | 216K | 47K | (80K) | (32K) | 468K | 491.4K | |
Non Current Liabilities Total | 361K | 468K | 387K | 49.3M | 116.7M | 122.5M | |
Net Tangible Assets | 416.6M | 240.0M | 196.1M | 197.4M | 227.0M | 184.4M | |
Retained Earnings Total Equity | (223.2M) | (425.5M) | (667.3M) | (962.7M) | (866.4M) | (823.1M) | |
Capital Surpluse | 639.6M | 665.4M | 863.5M | 1.2B | 1.3B | 1.4B | |
Property Plant Equipment | 1.2M | 1.0M | 1.6M | 601K | 691.2K | 734.4K | |
Net Invested Capital | 416.6M | 240.0M | 196.1M | 246.7M | 520.8M | 358.2M | |
Net Working Capital | 415.1M | 238.6M | 194.8M | 245.5M | 518.7M | 356.9M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Madrigal Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.Note that the Madrigal Pharmaceuticals information on this page should be used as a complementary analysis to other Madrigal Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Madrigal Stock analysis
When running Madrigal Pharmaceuticals' price analysis, check to measure Madrigal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Madrigal Pharmaceuticals is operating at the current time. Most of Madrigal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Madrigal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Madrigal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Madrigal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
CEOs Directory Screen CEOs from public companies around the world |
Is Madrigal Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (23.15) | Return On Assets (0.40) | Return On Equity (0.89) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.